Pilot randomized trial for treatment of bacterial vaginosis using in situ forming metronidazole vaginal gel

Abstract

Pilot testing showed that in situ MTZ vaginal gel is more effective than the conventional vaginal gel for long-term cure of BV. These findings suggest a novel and efficient long-term treatment of BV.

Antibacterial treatment of bacterial vaginosis: current and emerging therapies

“…One group in Egypt working on pluronic polymers, has developed a hydrogel that swells in aqueous environments for use as a drug delivery system. This novel vaginal delivery system for metronidazole, improved the therapeutic efficacy compared with that achieved with conventional vaginal gel 62. In a pilot randomized trial, while similar cure rates were reported after 1 week of treatment (85% in the new vaginal gel group and 71.4% in the conventional vaginal gel group; P = 0.294), the cure rate was significantly higher after 4 weeks in the new gel group compared with the conventional gel group (80% and 47%, respectively).…”

Development and characterization of thermosensitive pluronic-based metronidazole in situ gelling formulations for vaginal application

“…Clinical evaluation of formula F 7 in comparison with the marketed preparation (Tricho ® gel) in patients with bacterial vaginosis (20) showed that the cure rate after one week of treatment was 85 % in the in situ gel F 7 group and 71 % in the conventional vaginal gel group (Tricho ® gel), while after 4 weeks, the cure rate showed a significant difference in the in situ gel group compared to the conventional vaginal gel group (80 versus 47 %, respectively, p = 0.034). This shows that the in situ MTZ vaginal gel F 7 is more effective than the conventional vaginal gel product for sustained cure of bacterial vaginosis.…”

New strategies for local treatment of vaginal infections

“…Clinical study: improved efficacy after a 5 day treatment (twice daily app.) with significant difference in cure rate after 4 weeks versus Tricho ® Tgel (28ºC) [155,156].…”